New data from the Phase 2b Bridge–TIMI 73a trial have shown that the GalNAc3-conjugated antisense oligonucleotide (ASO) targeting apoC-III mRNA, olezarsen, significantly reduced triglyceride (TG) in patients with moderate hypertriglyceridaemia and elevated cardiovascular risk, or with severe hypertriglyceridaemia, who were already receiving standard-of-care lipid lowering therapy.1
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
